Astal Laboratories Limited , a leading chemical and specialty materials company, has achieved two significant milestones that are set to bolster its position in the European market.

REACH Certification: A Gateway to European Markets

Astal Laboratories has successfully obtained the REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) compliance certification. This certification is crucial for companies looking to export chemicals to the European Union, as it ensures adherence to EU chemical safety and environmental standards.

Key Points:

• The certification covers exports of specialty chemicals and advanced intermediates to the EU.
• It strengthens Astal's regulatory competencies and enhances access to high-value European markets.

Swiss Distribution Agreement

Following the REACH certification, Astal Laboratories has secured a Letter of Intent (LOI) from a Swiss-based distributor, marking a significant step in its international expansion.

Deal Details:

This agreement demonstrates the growing international demand for Astal's specialty chemical products and reflects confidence in the company's technical capabilities and regulatory-compliant manufacturing practices.

Management Commentary

Mr. Nikhil Chintalapati, COO/Spokesperson of Astal Laboratories Limited, commented on these developments:

"The receipt of the REACH Compliance Certificate is a significant achievement for Astal Laboratories. It not only enhances our regulatory standing but has already translated into commercial interest, as reflected by the Letter of Intent from our Swiss distribution partner. We look forward to serving the European market with high-quality, compliant products."

Company Outlook

These developments align with Astal Laboratories' commitment to:

• Regulatory excellence
• Global quality standards
• Expanding international footprint
• Innovation-driven growth

The REACH certification and the Swiss distribution agreement are expected to open new avenues for growth and strengthen Astal Laboratories' position in the global specialty chemicals market.

As the company moves forward with these new opportunities, investors and industry observers will be keen to see how these developments translate into financial performance and market share growth in the coming quarters.

Astal Laboratories Limited, a pharmaceutical company, has significantly increased its authorized share capital from Rs 20 crore to Rs 50 crore. This decision, approved by shareholders at an Extra Ordinary General Meeting (EGM) on November 6, 2025, marks a substantial expansion in the company's potential capital base.

Key Changes

The company has altered the Capital Clause V of its Memorandum of Association (MOA), resulting in the following modifications:

Corporate Action Details

• Date of Approval: November 6, 2025
• Approval Method: Extra Ordinary General Meeting
• Basis of Approval: Scrutinizer's Report dated November 6, 2025

Regulatory Compliance

Astal Laboratories Limited has duly informed the Bombay Stock Exchange (BSE) about this development on November 9, 2025. This notification aligns with the regulatory requirements under:

• Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
• Part A of Schedule III of the aforementioned regulations
• SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

Company Information

• CIN: L74120UP1993PLC015605
• Registered Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
• Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

This increase in authorized share capital provides Astal Laboratories with enhanced flexibility for potential future capital raising activities, which could be crucial for the company's growth and expansion plans. However, it's important to note that this change in authorized capital does not immediately impact the company's issued share capital or market capitalization. Investors and stakeholders should monitor future announcements for any plans related to the utilization of this expanded capital base.